Press Releases
|
Press ReleasesAugust 13, 2010 Cynapsus Therapeutics Reports Results for the Six Months Ended June 30, 2010Cynapsus Therapeutics Inc. (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the six months ended June 30, 2010. August 5, 2010 Cynapsus Announces Formation of Clinical Advisory Board For Parkinson’s ProgramCynapsus announced today the formation of an international Clinical Advisory Board (“CAB”). The CAB, which is made up of world class knowledge expert physicians, beginning with Dr. Warren Olanow and Dr. Fabrizio Stocchi, will provide counsel and guidance on a range of clinical design and management issues. August 4, 2010 Cynapsus Announces Additional Debenture FinancingCynapsus Therapeutics Inc. announced today that it has completed an additional financing of secured debentures in the aggregate amount of $180,000. July 29, 2010 Cynapsus Announces Addition of Dr. Albert Agro to Parkinson’s Program TeamCynapsus Therapeutics Inc. announced today that it has entered into an agreement with Dr. Albert Agro, an international clinical development expert in CNS diseases. July 27, 2010 Cynapsus Announces Parkinson’s Disease Survey ResultsCynapsus Therapeutics announced today the results of a survey of neurologists and movement disorder specialists relating to Parkinson’s (PD) practices and treatments, specifically targeted at analyzing the use of apomorphine products. July 26, 2010 Cynapsus Announces Signing of License Option Agreement of Parkinson’s Disease TechnologyCynapsus Therapeutics Inc. announced today that it has entered into a License Option Agreement with Adagio Pharmaceuticals Ltd. July 19, 2010 Cynapsus Announces Debenture FinancingCynapsus Therapeutics Inc. announced today that it has secured financing of secured debentures in the aggregate amount of $520,000. June 2, 2010 Cynapsus Amends Terms and Conditions of Brokered Private PlacementCynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) announced today that the terms and conditions for the previously announced brokered private placement have been amended due to market conditions. May 28, 2010 Cynapsus Therapeutics Reports Results for the Three Months Ended March 31, 2010Cynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the three months ended March 31, 2010. May 7, 2010 Cynapsus Confirms Terms and Conditions of Brokered Private PlacementCynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) announced today that the terms and conditions for the previously announced brokered private placement will remain as initially set, with each of the units (each a “Unit”) priced at $0.10 per Unit (the “Offering”) for gross proceeds of up to CDN$2,500,000. April 15, 2010 Cannasat Changes Name to Cynapsus TherapeuticsCannasat Therapeutics Inc. (CTH:TSX-V) (“Cannasat”) today announced that it received shareholder approval to change its corporate name to Cynapsus Therapeutics Inc. (“Cynapsus”). The approval was granted at the Annual General Shareholder Meeting held yesterday in Toronto. The Company’s stock symbol will remain as “CTH” on the TSX Venture Exchange. April 7, 2010 Cannasat Therapeutics Announces Private PlacementCannasat Therapeutics Inc. (CTH: TSX-V) today announced it intends to raise gross proceeds of up to CDN$2,500,000 through a brokered private placement of units at a price of $0.10 per Unit. April 6, 2010 Cannasat Therapeutics to Present at BioFinance 2010 ConferenceCannasat Therapeutics (CTH: TSX-V) announced today that Anthony Giovinazzo, President and Chief Executive Officer, will present an overview of the Company at the BioFinance 2010 Conference, being held this week in Toronto. March 9, 2010 BioTuesday: Cannasat Batting Hot Streak in its CNS TurnaroundNewly installed in the executive suite at Cannasat Therapeutics (TSX-V:CTH) last November, Mr. Giovinazzo’s mandate is to rebrand the company, founded in 2004 by Moses Znaimer to treat pain with a cannabinoid derivative, into a specialty central nervous system (CNS) drug company. March 5, 2010 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2009Cannasat Therapeutics Inc. (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting CNS diseases, today announced its results for the year ended December 31, 2009. March 4, 2010 IntelGenx and Cannasat Announce Letter of Intent for Relivar LicenseIntelGenx Corp. and Cannasat Therapeutics announced today that they have entered into a Letter of Intent (“LOI”). Under the terms of the LOI, IntelGenx would acquire a fifty percent ownership stake from Cannasat and an exclusive worldwide license to develop and commercialize Relivar, a novel formulation of dronabinol. February 4, 2010 Cannasat Announces Signing of Letter of Intent for In-licensing of Parkinson’s Disease TechnologyCannasat Therapeutics, a specialty clinical development pharmaceutical company targeting CNS illness, announced today that it has entered into a Letter of Intent (“LOI”) with Adagio Pharmaceuticals Ltd. granting Cannasat the option to execute a proposed exclusive, worldwide agreement to license all intellectual property relating to APL-130277, a reformulation of an approved Parkinson’s drug. February 1, 2010 Cannasat Update From Anthony Giovinazzo, President & CEOI want to take this opportunity to give you an update on our progress at Cannasat Therapeutics since my appointment as President and CEO on November 16th, 2009. January 11, 2010 Cannasat Therapeutics Strengthens its Board of DirectorsCannasat Therapeutics Inc., a specialty clinical development pharmaceutical company targeting diseases of the brain, announced today that Ron Hosking has joined its Board of Directors as an independent director. December 22, 2009 Cannasat Therapeutics Announces Debt for Shares SettlementCannasat Therapeutics, a specialty clinical development pharmaceutical company targeting diseases of the brain, today announced that it has agreed to settle $185,287 in debt by issuing 1,852,870 common shares at a deemed price of $0.10 per share. November 27, 2009 Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2009Cannasat Therapeutics (CTH: TSX-V), a clinical stage pharmaceutical company developing products to treat neurological disorders, today announced its results for the nine months ended September 30, 2009. November 16, 2009 Cannasat Therapeutics Announces New Chief Executive Officer: Anthony J. Giovinazzo, M.B.A., C.Dir.Cannasat Therapeutics announced today that Anthony J. Giovinazzo has been appointed to succeed David Hill as Chief Executive Officer, and joins the Company as President and Chief Executive Officer. August 31, 2009 Cannasat Therapeutics Completes Prospectus OfferingCannasat Therapeutics is pleased to announce that it has completed a second tranche of its previously announced short form prospectus offering of units. August 31, 2009 Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2009Cannasat Therapeutics, a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the six months ended June 30, 2009. August 6, 2009 Cannasat Therapeutics Completes First Tranche of Prospectus OfferingCannasat Therapeutics is pleased to announce that it has completed a first tranche of its previously announced short form prospectus offering of units. June 10, 2009 Cannasat Therapeutics Prices Offering of UnitsCannasat Therapeutics announced today that it has filed a final short form prospectus dated June 10, 2009 in each of the provinces of British Columbia, Alberta and Ontario for its previously announced offering of units. May 29, 2009 Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2009Cannasat Therapeutics Inc. (TSXV: CTH), a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the three months ended March 31, 2009. May 25, 2009 Cannasat Therapeutics Announces Favourable Decision from United States Patent and Trademark OfficeCannasat Therapeutics is pleased to announce today that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a U.S. Patent Application which forms the basis for Cannasat’s lead product, Relivar. May 19, 2009 Cannasat Therapeutics Files Preliminary Short Form ProspectusCannasat Therapeutics today announced that it has filed a preliminary short form prospectus with the securities regulatory authorities in the provinces of Ontario, British Columbia and Alberta in connection with a best efforts offering of units, each unit consisting of one common share and one common share purchase warrant. The offering to raise up to $2.5 million will be led by Sandfire Securities Inc. of Toronto. May 15, 2009 Cannasat Therapeutics names Nathan Bryson Chief Scientific OfficerCannasat Therapeutics today announced that Dr. Nathan Bryson, PhD, has been named Chief Scientific Officer, effective May 15, 2009. Dr. Bryson has more than 18 years of experience in pharmaceutical development, holds a BSc in Chemistry from Auburn University, and a PhD in Radiopharmaceutical Chemistry from the Massachusetts Institute of Technology (MIT). April 20, 2009 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2008TORONTO – Cannasat Therapeutics Inc. (TSXV: CTH), a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the year ended December 31, 2008. April 14, 2009 Cannasat and IntelGenx Announce Positive Phase 1(b) Results: Improved buccal tablet outperforms oral dronabinolCannasat Therapeutics, and its development partner IntelGenx Corp., today announced positive results for the Phase 1(b) clinical trial of Relivar, the first buccal dronabinol drug delivery product, which was developed using IntelGenx’ proprietary AdVersa buccal delivery technology. March 3, 2009 Cannasat Therapeutics Announces Closing of Private PlacementTORONTO – Cannasat Therapeutics Inc. (CTH - TSXV) ("Cannasat") is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of units ("Units") effective February 27, 2008. February 6, 2009 Cannasat Therapeutics Inc. Announces $600,000 FinancingToronto, Ontario - Cannasat Therapeutics Inc. (CTH : TSXV) announced today that it intends to conduct a non-brokered private placement of up to 6,000,000 Units of Cannasat at a price of $0.10 per Unit, for aggregate gross proceeds of up to $600,000 (the “Offering”). January 28, 2009 Cannasat to Commence Phase 1(b) Study of CAT 310, a Potential Treatment for Neuropathic PainCannasat Therapeutics Inc. ("Cannasat") (TSXV: CTH) and IntelGenx Corp. (OTCBB: IGXT, TSXV: IGX) ("IntelGenx"), announced today that Health Canada has approved Cannasat’s clinical trial application for a Phase 1(b) clinical study with its lead product, CAT 310. November 27, 2008 Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2008Cannasat Therapeutics Inc. (TSXV: CTH), a CNS drug development company, today announced its results for the nine months ended September 30, 2008. August 29, 2008 Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2008Cannasat Therapeutics Inc. (TSXV: CTH), a CNS drug development company, today announced its results for the six months ended June 30, 2008. August 12, 2008 Cannasat Therapeutics Announces Closing of Private PlacementCannasat Therapeutics Inc. is pleased to announce that it has closed a non-brokered private placement of units effective August 8, 2008. June 27, 2008 Cannasat Therapeutics Grant of Options and Share IssuanceCannasat Therapeutics Inc. announced today that it has granted options to acquire 1,000,000 shares in the capital of the Corporation effective June 25, 2008. June 23, 2008 Cannasat Therapeutics Receives $1.12 Million from Divesture of Prairie Plant Systems Equity PositionCannasat Therapeutics Inc. announced today that it has reached an agreement to sell the Company’s 12% equity stake in the privately-held, Saskatoon-based Prairie Plant Systems. May 22, 2008 Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2008Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the three months ended March 31, 2008. April 10, 2008 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2007Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the year ended December 31, 2007. March 18, 2008 Cannasat Therapeutics Announces Closing of Private PlacementCannasat Therapeutics Inc. is pleased to announce that it has closed a non-brokered private placement of units effective March 14, 2008. February 27, 2008 Cannasat Therapeutics Provides Update on Patent Application for Drug Development ProgramsCannasat Therapeutics, the developer of novel cannabinoid-based pharmaceutical products, announced that it has received a favorable decision from the United States Patent and Trademark Office (USPTO). January 14, 2008 Cannasat Therapeutics appoints Dr. Julia Levy to Board of DirectorsCannasat Therapeutics today announced that Dr. Julia Levy has been appointed to its Board of Directors. Dr. Levy is a Canadian pharmaceutical industry leader and brings years of drug discovery, development, and commercialization experience to the Cannasat Board. January 14, 2008 Cannasat Therapeutics appoints Dr. Julia Levy to Board of DirectorsCannasat Therapeutics today announced that Dr. Julia Levy has been appointed to its Board of Directors. Dr. Levy is a Canadian pharmaceutical industry leader and brings years of drug discovery, development, and commercialization experience to the Cannasat Board. December 4, 2007 Cannasat and IntelGenx Complete Phase 1 Study for CAT 310Cannasat Therapeutics announced today the successful completion of its first Phase 1 clinical trial. Results of the randomized, single dose, crossover study comparing two different formulations of the product demonstrated that administration of CAT 310 was safe and well-tolerated with no serious adverse events. November 28, 2007 Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2007Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the nine months ended September 30, 2007. November 8, 2007 Cannasat Therapeutics Retains Leading Investor Relations FirmCannasat Therapeutics today announced that it has retained The Equicom Group ("Equicom") to provide the Company with strategic investor relations and financial communications services. October 30, 2007 Cannasat Therapeutics Appoints George Nomikos as Senior Director, Scientific AffairsCannasat Therapeutics today announced that George Nomikos, former Scientific Director at Amgen, Inc. has been appointed as Senior Director, Scientific Affairs. Dr. Nomikos has published more than 140 papers in the field of Neuroscience, Neuropsychopharmacology and Cannabinoid Therapeutics, and brings invaluable knowledge and experience to the Cannasat drug development team. September 17, 2007 Cannasat Therapeutics and IntelGenx Corp. Reach Key MilestoneCannasat Therapeutics Inc., a company specializing in the development of cannabinoid-based pharmaceutical products, announced today the commencement of a Phase 1 clinical study of its lead product, CAT 310, a potential treatment for neuropathic pain. August 28, 2007 Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2007Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the six months ended June 30, 2007. August 23, 2007 Cannasat Therapeutics to Commence Phase 1 Study of CAT 310, a Potential Treatment for Neuropathic PainCannasat Therapeutics announced today that Health Canada has approved Cannasat’s clinical trial application for a Phase 1 clinical study with its lead product, CAT 310. June 26, 2007 Cannasat Therapeutics appoints Dr. David Pattenden as Chairman of the BoardCannasat Therapeutics Inc. announced today that Dr. David Pattenden has been appointed Chairman of the Board. May 23, 2007 Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2007Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the three months ended March 31, 2007. April 25, 2007 Cannasat Therapeutics Reports Results for the Year Ended December 31, 2006Cannasat Therapeutics, the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the year ended December 31, 2006. April 25, 2007 Cannasat Therapeutics Inc. Announces Closing of Private PlacementCannasat Therapeutics is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of units ("Units"). Cannasat issued an aggregate of 3,790,226 Units at a price of C$0.22 per Unit raising gross proceeds of C$833,849.90. March 20, 2007 Cannasat Therapeutics and IntelGenx enter into agreement to develop cannabinoid-based products for the treatment of mood disorders such as anxiety and depression.Cannasat Therapeutics and IntelGenx today announced a long-term collaborative agreement to co-develop a novel cannabinoid-based product, CAT 320, through a combination of Cannasat’s and IntelGenx’s proprietary drug delivery technologies. December 8, 2006 Cannasat Therapeutics Inc. Grant of Options and Share IssuanceCannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, announced today that it has granted options to acquire 891,240 shares in the capital of the Corporation effective December 4, 2006. December 6, 2006 Cannasat Therapeutics Announces Successful pre-CTA Meeting with Health Canada Regarding CAT 310Cannasat Therapeutics Inc. is pleased to announce a successful pre-CTA (“Clinical Trial Application”) meeting with Health Canada for Phase 1 testing of its lead product, CAT 310, a cannabinoid based pharmaceutical product. November 29, 2006 Cannasat Therapeutics Reports Interim Results For The Nine Months Ended September 30, 2006Cannasat Therapeutics Inc., the developer of novel cannabinoid-based pharmaceutical products, today announced its interim results for the nine-months ended September 30, 2006. November 14, 2006 Cannasat Therapeutics and IntelGenx Enter into a Collaborative Agreement to Develop Novel Cannabinoid-based Products Based on Proprietary Drug Delivery TechnologiesCannasat Therapeutics Inc. and IntelGenx Corp. today announced a long-term collaborative agreement to co-develop novel cannabinoid-based products through a combination of Cannasat’s and IntelGenx’s proprietary drug delivery technologies. The collaboration will focus on the development and production of new formulations of cannabinoid pharmaceutical products, starting with Cannasat’s lead product, CAT 310. November 7, 2006 Cannasat Therapeutics Inc. announces NRC-IRAP funding for CAT 210Cannasat Therapeutics Inc. is pleased to announce a contribution agreement with the National Research Council Canada Industrial Research Assistance Program (“NRC-IRAP”) for pre-clinical research and development of CAT 210. CAT 210 is Cannasat’s second product in development that targets the treatment of neuropathic pain with cannabinoids. August 3, 2006 Cannasat Therapeutics Inc. Announces Closing of Private PlacementCannasat Therapeutics Inc. is pleased to announce that it has closed the non-brokered private placement of units previously announced on July 21, 2006. July 21, 2006 Cannasat Therapeutics Inc. Announces New Terms for a Private Placement FinancingCannasat Therapeutics Inc. announced today that due to market conditions it has revised its proposed financing previously announced on June 6, 2006. June 7, 2006 Cannasat Therapeutics Inc. Announces $5.0 Million FinancingCannasat Therapeutics Inc. is pleased to announce that it has entered into an engagement letter concerning a private placement, on a best efforts basis, of up to 15,151,515 Units of Cannasat at a price of C$0.33 per Unit, for aggregate gross proceeds of approximately C$5,000,000. June 5, 2006 Cannasat Therapeutics Inc. Announces New Director and Releases Q1 2006 Financial StatementsCannasat Therapeutics Inc. is pleased to announce the addition of Peter Palframan to the Board of Directors. April 5, 2006 Cannasat Therapeutics now public on the TSX Venture ExchangeMoses Znaimer, Chairman of Cannasat Therapeutics Inc., is pleased to announce that the Company is now a public entity and is trading on the TSX Venture Exchange, under the symbol "CTH" March 22, 2006 Cannasat Therapeutics Inc. and Lonsdale Public Ventures Inc. Announce Completion of Qualifying TransactionCannasat Therapeutics Inc. announced the completion of the amalgamation of Lonsdale and Cannasat Therapeutics Inc. to form a new company with the name "Cannasat Therapeutics Inc." under the provisions of the Business Corporations Act. February 8, 2006 Lonsdale Public Ventures Inc. Announcement Concerning Qualifying Transaction with Cannasat Therapeutics Inc.Lonsdale Public Ventures Inc. announced today further details of its agreement in principle to acquire Cannasat Therapeutics Inc. October 5, 2005 Lonsdale Public Ventures Inc. Announces Letter Of IntentLonsdale Public Ventures Inc., a Capital Pool Company, announces that it has entered into a letter of intent concerning the amalgamation of Lonsdale and Cannasat Therapeutics Inc. |
|
|
| About Cynapsus |  | Relivar Product | | APL-130277 Product | | Investor Relations | | Contact & Legal | | Copyright 2010, Cynapsus Therapeutics Inc. All rights reserved. |